SOURCE: Amarillo Biosciences, Inc.

March 21, 2007 13:23 ET

Amarillo Biosciences Issues Clinical Progress Report and Schedules Annual Meeting

AMARILLO, TX -- (MARKET WIRE) -- March 21, 2007 --Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today issued the following progress report on two of its clinical studies:

Enrollment in Turkish Behçet's Disease

Nobel Ilac Sanayii Ve Ticaret A.S., the leading Turkish pharmaceutical company that is co-sponsoring a Behçet's Disease study with ABI, has confirmed that two new clinical sites have been approved by the Turkish Ministry of Health to commence enrollment of patients with Behçet's disease. Two new sites are being added to accelerate enrollment of 90 patients with the goal of completing the Phase 2 trial in 2007. Approximately 90 patients have been screened for enrollment and 59 have been started on treatment as of today's date. The double-blinded Phase 2 study is testing the efficacy of interferon lozenges versus placebo in the treatment and prevention of mouth ulcers. The treatment duration is 12 weeks. Other products used to treat mouth ulcers in Behçet's Disease, such as corticosteroids, have significant side effects. ABI's non-toxic oral interferon product potentially represents a substantial improvement in the treatment of the mouth ulcers suffered by virtually all Behçet's Disease patients.

Enrollment in Phase 2 Clinical Trial of Oral Warts in HIV+ Patients

Three more clinical sites have agreed to join the six clinical sites currently approved to enroll patients in a study of HIV+ patients suffering from oral warts. This placebo-controlled Phase 2 study is a follow-up to two successful studies that have already been completed. In the most recent study, 57% of HIV patients given the optimum dose of oral interferon experienced a complete or almost complete clearance of their oral warts. No products are currently approved by the FDA for this condition, so treatment of oral warts represents a unique market for ABI. As of today's date, 7 of 80 planned subjects have been enrolled. The goal is to complete the study in 2007.

Separately, the company announced that its annual shareholder's meeting will be held in Amarillo, Texas on Friday, June 22, 2007. The location and time of the meeting will be included in the proxy statements.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    Tel: 800-477-7570
    Tel: 212-344-6464
    Fax: 212-618-1276
    e-mail: Email Contact

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301
    e-mail: Email Contact